Superworth

Pro DEX PDEX

Medical - Instruments & Supplies, Healthcare
$57.65
−0.88%
Market cap
$184.5M
PE
15.9×
10y median 16.5×
Forward PE
n/m
not a meaningful number
Price to sales
2.3×
EV/EBIT
14.8×
Revenue, 12 months
$79.6M
+13% on a year ago
Net margin
15.1%
Free cash flow yield
5.8%

Pro DEX trades at 15.9× trailing earnings, near its ten-year median. Revenue was $79.6M over the last twelve months, up 13% on a year earlier with a 15% net margin.

Charts

Financials

Income statement for PDEX, by quarter
Income statementQ2 FY24Q3 FY24Q4 FY24Q1 FY25Q2 FY25Q3 FY25Q4 FY25Q1 FY26Q2 FY26Q3 FY26Q4 FY26Q1 FY27
$12.6M+12%$14.3M+9%$15M+41%$14.9M+25%$16.8M+33%$17.4M+22%$17.5M+16%$18.5M+24%$18.7M+11%$19.9M+15%$20.4M+17%$20.6M+11%
Cost of revenue$9.8M+13%$10.3M+11%$10.9M+50%$9.7M+18%$11.7M+20%$11.6M+13%$14M+28%$13.2M+35%$12.9M+10%$13.8M+19%$13.3M−5%$13.7M+4%
Gross profit$2.8M+7%$4M+5%$4.1M+22%$5.2M+41%$5.1M+81%$5.8M+45%$3.5M−15%$5.4M+4%$5.7M+13%$6.1M+6%$7.1M+103%$6.9M+28%
R&D$788K+69%$760K+7%$836K+20%$843K+5%$942K+20%$947K+25%$905K+8%$768K−9%$734K−22%$827K−13%$1M+12%$1.2M+58%
SG&A$1.2M+21%$1M−0%$902K−14%$1.3M+27%$1.4M+16%$1.2M+18%$1.2M+38%$1.5M+15%$1.8M+22%$2.2M+83%$2.5M+105%$2.1M+43%
$777K−32%$2.2M+7%$2.4M+46%$3M+64%$2.7M+247%$3.6M+65%$1.3M−43%$3.1M+3%$3.3M+21%$3.1M−15%$3.5M+163%$3.5M+13%
Interest expense$139K+9%$138K+5%$149K+4%$152K+14%$204K+47%$246K+78%$227K+52%$200K+32%$141K−31%$201K−18%$270K+19%$260K+30%
Pre-tax income$620K−84%$913K−58%$1.9M−4%$3.3M$2.6M+317%$4.6M+399%$1.6M−17%$6.2M+88%$2.9M+13%$5.3M+17%$3.5M+121%$3.4M−46%
$120K−88%$258K−55%$343K−33%$853K$546K+355%$1.3M+396%$402K+17%$1.5M+81%$741K+36%$1.4M+10%$668K+66%$331K−79%
Net income$500K−82%$655K−60%$1.6M+6%$2.5M$2M+308%$3.3M+400%$1.2M−25%$4.7M+90%$2.2M+7%$3.9M+20%$2.9M+139%$3M−35%
$0.14−81%$0.19−58%$0.46+10%$0.75$0.61+336%$0.98+416%$0.36−22%$1.40+87%$0.66+8%$1.20+22%$0.85+136%$0.92−34%
3.6M−1%3.5M−3%3.5M−3%3.3M−7%3.3M−8%3.3M−5%3.3M−4%3.3M+1%3.3M−1%3.3M−2%3.4M+1%3.3M−1%

EPS, diluted: 20 periods, Q4 FY11 to Q4 FY26: quarter's net income to common over its shares, to the cent.

Diluted shares: 14 periods, Q4 FY11 to Q4 FY26: share-days: the 12-month average less the 9-month, weighted by days. Q4 FY12 and Q4 FY13: a loss quarter: its basic count, share-days: the 12-month average less the 9-month, weighted by days.

From each company's 10-Q and 10-K filings, the newest version of each figure. Quarters are as filed (a fourth quarter is the year less its first nine months), fiscal years as the 10-K prints them, restated where a later 10-K restated them, and balance sheet lines as of the period's end. A quarter whose 10-Q isn't filed yet is from the company's results release. Growth is on the same period a year earlier. A dash is a period with no figure for the line: the filing doesn't print it, or it hasn't been read yet.

Peers

Companies in Medical - Instruments & Supplies nearest Pro DEX's size, closest first.

CompanyMarket capPEIts 10y median PEFwd PEP/SRevenue growthNet margin
PDEXPro DEX$184.5M15.9×16.5×2.3×+13%15.1%
UTMDUtah Medical Products$224.6M21.5×20.9×6.2×−7%29.0%
INFUInfuSystem$275.7M33.8×43.5×1.9×+2%6.0%
EMBCEmbecta$350.7M4.2×11.6×0.3×−8%8.6%
KEQUKewaunee Scientific$96.7M12.1×13.6×0.3×+5%3.0%
TCMDTactile Systems Technology$518.1M21.2×62.3×1.5×+17%7.1%
APTAlpha Pro Tech$56.3M13.5×14.8×0.9×+6%6.8%
MOVMovado$710.9M17.7×13.4×1.0×+5%6.0%
NEPHNephros$35.2M20.3×28.3×1.7×+24%8.4%
IRMDIradimed$1B42.5×41.5×11.4×+11%26.8%
IARTIntegra Lifesciences$1.1B80.1×46.3×0.6×+1%0.8%
Peer median$313.2M20.7×24.6×1.3×+5%6.9%

More on Pro DEX

Each number over time

Where it ranks

Its groups

About

Industry
Medical - Instruments & Supplies
Sector
Healthcare

Valuation data, not investment advice. Prices as of .